Welcome to our dedicated page for Geovax Labs SEC filings (Ticker: GOVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GeoVax Labs, Inc. (GOVX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures, giving investors a structured view of its capital markets activity, governance decisions, and development funding. As a smaller reporting company, GeoVax files registration statements, current reports, and proxy materials that outline its financing transactions, stockholder approvals, and contractual arrangements.
Through registration statements on Form S-1 and Form S-3, GeoVax registers offerings of common stock and warrants, as well as the resale of warrant shares issued in private placements. These filings describe offerings such as registered direct financings and concurrent private placements of common warrants, the number of shares and warrants involved, and intended uses of proceeds, including research and development, manufacturing, clinical studies, capital expenditures, and working capital.
Form 8-K current reports provide details on material events, including the pricing and closing of offerings, entry into placement agency and purchase agreements, government contract developments, and the release of quarterly financial results. 8-K filings also cover special stockholder meetings and the outcomes of votes on proposals such as warrant share issuance approvals and reverse stock split authorizations.
Proxy materials, such as the DEF 14A special meeting proxy statement, outline proposals submitted to stockholders, the rationale for actions like reverse stock splits or warrant exercise approvals, and the mechanics of voting. In addition, Form 25 filings document the removal from listing and/or registration of specific GeoVax securities, such as warrants, from Nasdaq Stock Market LLC.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain complex documents in plain language. Investors can quickly see the key terms of financing agreements, understand the implications of stockholder votes, and track how government contracts like the BARDA/Project NextGen award are reflected in the company’s disclosures. Real-time updates from EDGAR ensure that new 8-Ks, S-1s, proxy statements, and other filings are available promptly, while dedicated sections for warrant-related disclosures and capital structure changes help users follow the evolution of GOVX’s securities over time.
GeoVax Labs, Inc. is calling a June 17, 2026 annual stockholder meeting in Atlanta to elect seven directors, approve two key warrant-exercise share issuances, ratify its independent auditor, and hold advisory votes on executive pay and the future frequency of say‑on‑pay votes.
The proxy details board structure, director and executive biographies, compensation, equity plans, and large 2025–2026 capital raises using common stock, pre‑funded warrants, and common warrants, including new February and March 2026 warrant structures that require stockholder approval before full exercise.
GeoVax Labs, Inc. filed a Post-Effective Amendment No. 3 to its Form S-1 to add Exhibit 23.1 (Consent of Independent Registered Public Accounting Firm) that was inadvertently omitted from the prior post-effective amendment. The filing includes an estimated expense schedule totaling $16,135 (SEC registration fee $635).
The document also discloses recent issuances of restricted common stock and private placement agreements, including issuance of 11,883, 4,892 and 6,703 restricted shares in 2023–2024 and private placement commitments for up to 11,904,768 common shares issuable upon exercise of warrants (September 30, 2025) and up to 865,804 such shares (February 12, 2026). The amendment is signed by the CEO and principal officers.
GeoVax Labs, Inc. filed Post-Effective Amendment No. 3 to its Form S-1 to add Exhibit 23.1 (consent of independent registered public accounting firm) that was omitted from the prior post-effective amendment.
The filing also lists estimated issuance expenses, including an $1,034 SEC registration fee and $16,534 total expenses. It discloses recent unregistered issuances: 11,883, 4,892 and 6,703 restricted shares issued under service/consulting agreements, and private placement commitments for up to 11,904,768 shares issuable upon warrant exercise and up to 865,804 shares issuable upon exercise under a February 12, 2026 purchase agreement.